Business
EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule
- DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass., Nov.
About this update from Eyepoint, Inc.
[{"type":"text","content":"- DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees -\n WATERTOWN, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs (VA) for DEXYCU® and YUTIQ® to be included on the Federal Supply Schedule (FSS), providing U.S. veterans and other federal government agencies with access to both products. The VA FSS contract will extend access to Eyepoint products to over nine million VA beneficiaries and others within the federal system. The final VA contract is expected to be executed in the next few months and have a five-year term. “This new agreement with the VA further extends the commercial reach of DEXYCU and YUTIQ to patients suffering from ocular diseases in areas of high unmet medical need,” said Nancy Lurker, President and CEO of EyePoint Pharmaceuticals. “Our commercial launch efforts have yielded a positive reception with physicians and an increased product demand from ambulatory surgical centers for DEXYCU and uveitis specialists for YUTIQ. We are extremely proud that U.S. veterans and other federal employees will now be offered access to our innovative ophthalmic products, increasing patient access to an additional nine million beneficiaries.” About EyePoint Pharmaceuticals EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com), headquartered in Watertown, MA, is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. With the approval by the FDA on October 12, 2018 of the YUTIQ® three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, the Company has developed five of the six FDA-approved sustained-release treatments for eye diseases. The most common adverse reactions reported for YUTIQ were cataract development and increases in intraocular pressure. DEXYCU® was approved by the FDA on February 9, 2018. DEXYCU, administered as a single intraocular dose at the end of ocular surgery for the treatme...